Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose nerinetide for acute ischemic stroke undergoing endovascular thrombectomy without thrombolysis
2020-002360-30Phase 3Completed
- Sponsor
- NoNO Inc.
- Start
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Nerinetide single dose with Placebo single dose (2 arms). Primary endpoint: Global disability reduction. Started Sep 2020; status: completed.
02
Drugs
nerinetide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2020-002360-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002360-30.